Phase 3 Study: Daratumumab in Combination with Lenalidomide plus Dexamethasone Induces Clonality Increase and T-Cell Expansion
Daratumumab in combination with lenalidomide plus dexamethasone specifically induces robust increases in T-cell clonality. The finding provides support for an immune modulatory mechanism of daratumumab.
Outcomes of patients with relapsed/refractory multiple myeloma are poor, but are improving as treatment options expand.
Daratumumab Prolongs Survival Compared with Standard of Care in Patients with Heavily Pretreated and Highly Refractory Multiple Myeloma
Compared with standard-of-care therapies delivered in a real-world setting, daratumumab monotherapy extends overall survival in patients with heavily pretreated and highly refractory multiple myeloma.
Researchers reported results of a real-world prospective study that evaluated different geriatric assessment tools and comorbidity indices as well as standard disease-related prognostic factors in consecutive unselected patients aged >65 years with symptomatic multiple myeloma (MM).
Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States
Researchers reported results of a population-based study examined sex, race, and age-stratified differences in incidence, mortality, and survival from 1973 to 2012 for 89,867 myeloma patients by using national epidemiologic data.
The Significant Contribution of Pain in Determining the Health Status of Patients with Multiple Myeloma
Researchers presented results of patient-reported assessments of general health status as well as pain severity and interference using pooled data from 3 denosumab registrational trials that had enrolled patients with advanced cancers including multiple myeloma (MM).
Researchers reported results of an analysis using national epidemiologic data and self-reported data from the Medicare Health Outcomes Survey that determined the prevalence of falls in older adults with newly diagnosed multiple myeloma (MM) and examined associations between falls and functional status, comorbidities, and self-reported health.
Beth Faiman elaborates on her idea wish list of resources and tools that would help her to better manage patients on oral oncolytics.
Ali McBride provides an overview of the role of the pharmacist and the importance of working with a broad team of healthcare providers in managing patients on oral oncolytics.
Beth Faiman argues that patient support services are integral in her role as a nurse because they aid in getting patients the treatments they need, promote adherence, and provide patient education.
Page 12 of 16
Results 111 - 120 of 159
Results 111 - 120 of 159